UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility

The pharmacogenomics journal, 2009-10, Vol.9 (5), p.341-346

2009

Volltextzugriff (PDF)

Zoledronic acid in patients with adenocarcinoma of the prostate M1

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14623-14623

2006

Volltextzugriff (PDF)

Phase II screening study of an LHRH analog, dexamethasone and somatostatin analog versus LHRH analogue with dexamethasone in HRPC

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15579-15579

2007

Volltextzugriff (PDF)

Zolendronic acid in patients with adenocarcinoma of the prostate M1

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4777-4777

2005

Volltextzugriff (PDF)

Fas-670 polymorphism and prostate cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.21028-21028

2007

Volltextzugriff (PDF)

Phase III study of intermitent monotherapy versus continuous combined androgen deprivation

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5125-5125

2007

Volltextzugriff (PDF)

Five years survival and risk of death in a phase III study of intermmittent monotherapy versus continuous combined androgen deprivation

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16034-16034

2008

Volltextzugriff (PDF)

Evaluation of quality-of-life side effects and duration of therapy in a phase III study of intermittent monotherapy versus continuous combined androgen deprivation

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5064-5064

2008

Volltextzugriff (PDF)

Phase III intermittent MAB vs continuous MAB

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4513-4513

2006

Volltextzugriff (PDF)

Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

Oncology, 2003-01, Vol.65 Suppl 1, p.24-28

2003

Volltextzugriff (PDF)

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer : a subanalysis of EORTC trial 30853

Cancer, 1990-09, Vol.66 (5), p.1009-1016

1990

Volltextzugriff (PDF)

Zoledronic acid in M1 patients: HRPC versus hormonal sensitive

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16120-16120

2008

Volltextzugriff (PDF)

INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL

The Journal of urology, 2001-08, Vol.166 (2), p.476-481

2001

Volltextzugriff (PDF)

Phase II protocol with docetaxel plus prednisone in patients with hormone refractory prostate cancer in two groups: With previous chemotherapy and without chemotherapy

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16118-16118

2008

Volltextzugriff (PDF)

Quality of life in patients with prostatic cancer a feasibility study

Cancer, 1993-02, Vol.71 (S3), p.1138-1142

1993

Volltextzugriff (PDF)

Quality of life in prostatic cancer patients

Cancer, 1993-12, Vol.72 (S12), p.3803-3806

Calais Silva, F. Da

1993

Volltextzugriff (PDF)

Phase II screening study of a LHRH analogue, dexamethasone and somatostatin analogue versus LHRH analogue with dexamethasone in HRPC

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16082-16082

2008

Volltextzugriff (PDF)

The relationship between biochemical failure and TP53 genetic polymorphism in patients with prostate cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5133-5133

2007

Volltextzugriff (PDF)

Cytokine gene polymorphism: Influence in the response of bladder superficial carcinoma to the immunotherapeutic with BCG

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5081-5081

2007

Volltextzugriff (PDF)

Phase II study 2000mg of intravesical gemcitabine in marker lesions

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4593-4593

2005

Volltextzugriff (PDF)

Phase II screening study to assess the combination of a LHRH analogue, dexamethasone and a somatostatin analogue versus a LHRH analogue with dexamethasone in hormone refractory prostate cancer patients

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4565-4565

2006

Volltextzugriff (PDF)

Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized Trial

The Journal of urology, 1993-01, Vol.149 (1), p.77-82

1993

Volltextzugriff (PDF)

Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer

Oncology, 2003-01, Vol.65 (Suppl 1), p.24-28

2003

Volltextzugriff (PDF)

Phase II study of oral vinorelbine plus hormone therapy in hormone-refractory prostate cancer

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16075-16075

2008

Volltextzugriff (PDF)

Combination Chemotherapy with Cisplatin and Methotrexate in Advanced Transitional Cell Cancer of the Bladder

The Journal of urology, 1987-04, Vol.137 (4), p.663-667

1987

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

KollektionPublisher website

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility

Zoledronic acid in patients with adenocarcinoma of the prostate M1

Phase II screening study of an LHRH analog, dexamethasone and somatostatin analog versus LHRH analogue with dexamethasone in HRPC

Zolendronic acid in patients with adenocarcinoma of the prostate M1

Fas-670 polymorphism and prostate cancer

Phase III study of intermitent monotherapy versus continuous combined androgen deprivation

Five years survival and risk of death in a phase III study of intermmittent monotherapy versus continuous combined androgen deprivation

Evaluation of quality-of-life side effects and duration of therapy in a phase III study of intermittent monotherapy versus continuous combined androgen deprivation

Phase III intermittent MAB vs continuous MAB

Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer : a subanalysis of EORTC trial 30853

Zoledronic acid in M1 patients: HRPC versus hormonal sensitive

INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL

Phase II protocol with docetaxel plus prednisone in patients with hormone refractory prostate cancer in two groups: With previous chemotherapy and without chemotherapy

Quality of life in patients with prostatic cancer a feasibility study

Quality of life in prostatic cancer patients

Phase II screening study of a LHRH analogue, dexamethasone and somatostatin analogue versus LHRH analogue with dexamethasone in HRPC

The relationship between biochemical failure and TP53 genetic polymorphism in patients with prostate cancer

Cytokine gene polymorphism: Influence in the response of bladder superficial carcinoma to the immunotherapeutic with BCG

Phase II study 2000mg of intravesical gemcitabine in marker lesions

Phase II screening study to assess the combination of a LHRH analogue, dexamethasone and a somatostatin analogue versus a LHRH analogue with dexamethasone in hormone refractory prostate cancer patients

Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized Trial

Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer

Phase II study of oral vinorelbine plus hormone therapy in hormone-refractory prostate cancer

Combination Chemotherapy with Cisplatin and Methotrexate in Advanced Transitional Cell Cancer of the Bladder

Aktive Filter

Suchergebnisse filtern